ESMO 2017 | How has the trabectedin extended access program benefited sarcoma patients?
Sarcomas are often diagnosed in patients who are approximately 60 years of age. Robin Jones, BSc, MB BS, MRCP, MD (Res), from The Royal Marsden NHS Foundation Trust, London, UK discusses the extent of treatment options historically available for this disease, and explains why the trabectedin extended access program (NCT01427582) was so important. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up